Pidsr Cif
Pidsr Cif
Pidsr Cif
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
Influenza-like Illness
Leptospirosis
Malaria
Non-neonatal Tetanus
Pertussis
Typhoid and Paratyphoid Fever
_____ Rabies
_____ Severe Acute Respiratory Syndrome
(SARS)
_____ Outbreaks
Clusters of diseases
Category I: Notify simultaneously the PHO, CHD and NEC within 24 hours of detection and send advance copy of
the Case Investigation Form (CIF) as soon as possible.
Category II: Report all cases of notifiable diseases/syndromes every FRIDAY of the week to the next higher level
using the Case Report Form (CRF).
Reminder: Submission of report is every FRIDAY of the week. The weekly report should include this page (Summary Page) ,
Case Investigation Forms (CIF) and the Case Report Forms (CRF).
Page 1 of 2
Philippine Integrated Disease
Surveillance and Response
Type: RHU
Govt Laboratory
Address:
I. PATIENT
INFORMATION:
Patient Number:
Private Laboratory
Middle Name
Complete Address:
Male
Sex:
Female
ILHZ:
Clinic
Airport/Seaport
Last Name
MM
District:
Private Hospital
DD
YY
Age:
Date of
Birth:
Days
Months
Years
MM
DD
YY
MM
DD
YY
Deep
Tendon
Reflexes
Motor
Status
YY
Date of Report:
Date of Investigation:
PRODROME
Fever: Y N U
Cough: Y N U
Diarrhea/Vomiting:
Y N U
Muscle pain:
Y N U
Meningeal signs:
Y N U
PARALYSIS
Sensory
Status
Right arm: Y N U
Left arm:
Y N U
Right leg:
Y N U
PROGRESSION
Paralysis fully developed within 3
to 14 days from onset of illness?
Y N U
Left leg:
Y N U
Direction of paralysis:
Ascending Descending
Unknown
Breathing muscles: Y N U
Y N U
_____________________________
Did the patient travel (>10 km from house) one month prior to illness? Y N U
If YES, specify place:____________________________________
V. LABORATORY DATA
Stool
sample #
Collected?
If YES, date
taken
Date sent to
Date received RITM
RITM
Y N
___/___/___
___/___/___
Y N
___/___/___
___/___/___
Adequate? Y N
Result
Date result
___/___/___
NEG 1 2 3 NPEV
Other, specify______________________
___/___/___
___/___/___
NEG 1 2 3 NPEV
Other, specify______________________
___/___/___
If NO, reason for no examination: Patient died Lost to follow -up Other, specify____________________
Atrophy?: Y N U
Other observations:_____________________________________________
175
Page 2 of 2
IF VAPP
Recipient VAPP
Contact VAPP
Unknown
CLASSIFICATION CRITERIA
FINAL DIAGNOSIS
Laboratory
EPI linked
Lost to follow -up
Death
With residual paralysis
Without residual paralysis
Any child less than 15 years of age with acute flaccid paralysis, OR
A person of any age in whom poliomyelitis is suspected by a physician.
An AFP case that is <5 years old with < 3 doses of OPV and has fever at the onset of asymmetrical paralysis,
OR
An AFP case or a person of any age whose stool specimen(s) has poliovirus isolate.
= 25% = Absent
100% = Normal
B. Deep tendon reflexes (DTRs) are presented in (+) symbol and categorized as follows:
none or 0 = absent
++ = normal
= reduced
1/5 to 3/5 = reduced movement (with movement but not against resistance or gravity)
4/5 to 5/5 = normal (movement with full resistance and against gravity)
176
Page 1 of 2
Anthrax
(ICD 10 Code: A22)
Name of DRU:
Type: RHU
Address:
Govt Laboratory
Patient Number:
I. PATIENT
INFORMATION:
Private Laboratory
Middle Name
Male
Sex:
Female
Clinic
Airport/Seaport
Last Name
MM
Complete Address:
District:
Occupation:
Private Hospital
DD
YY
Age:
Days
Months
Years
Date of
Birth:
ILHZ:
Name Workplace:
Address of Workplace:
II. CLINICAL
INFORMATION:
Signs and
Symptoms:
Admitted?
Yes No Unknown
Fever
Upset stomach (nausea)
Headache
Dry cough
Sore throat
Trouble swallowing
Trouble breathing
Date Admitted/
Seen/Consult
MM
DD
Stomach pain
Vomiting blood
Bloody diarrhea
Sweating excessively
Extreme tiredness
Pain or tightness in the chest
Sore muscles
YY
Date Onset of
Illness
MM
DD
YY
Neck pain
Itchy skin
Black scab on skin
Skin lesions
Describe lesion: ____________
_________________________
III. POTENTIAL RISK FACTORS IN THE 15-60 DAYS PRIOR TO ONSET OF SIGNS/SYMPTOMS
Y N U
Y N U
Has the patient been exposed to Anthrax Vaccine or to anthrax -vaccinated animals?
Y N U
Does the patient have occupational or other exposure to hides, wool, furs, bone meal or other animal products?
Y N U
Contact with live or dead animals? (cattle, sheep, goats, horses, pigs and other herbivores both livestock and wildlife)
Y N U
Does the patient have a history of travel beyond his/her usual place of residence/surroundings?
Y N U
Y N U
Y N U
Has the patient eaten undercooked meat? (cattle, sheep, goats, horses, pigs and other herbivores both livestock and wildlife)
Y N U
Did the patient receive unusual letters or packages? (e.g. containing threats or unusual messages)
Y N U
Y N U
Was the patient present or nearby when an envelope that contained any form of powder was opened?
CASE CLASSIFICATION
OUTCOME
Cutaneous
Gastrointestinal
Suspected Case
Alive
Pulmonary
Probable Case
Died,
Meningeal
Confirmed Case
Unknown
Unknown
V. LABORATORY TESTS:
Specify
Specimen
If YES, date
taken
MM
MM
DD
DD
Type of laboratory
test done
Results
N=Negative; I=Indeterminate; U-Unknown
YY
Positive for:
N I U
Positive for:
N I U
YY
Date result
MM
DD
YY
MM
DD
YY
179
Page 2 of 2
Anthrax
CASE DEFINITION/CLASSIFICATION:
Suspected case: A person with acute onset of illness characterized by several clinical forms as follows:
a. localized form:
1. cutaneous: skin lesion evolving over 1 to 6 days from a papular through a vesicular stage, to a depressed
black eschar invariably accompanied by edema that may be mild to extensive;
b. systemic forms:
1. gastro-intestinal: abdominal distress characterized by nausea, vomiting, anorexia and followed by fever;
2. pulmonary (inhalation): brief prodrome resembling acute viral respiratory illness, followed by rapid onset of
hypoxia, dyspnea and high temperature, with X-ray evidence of mediastinal widening;
3. meningeal: acute onset of high fever possibly with convulsions, loss of consciousness, meningeal signs and
symptoms; commonly noted in all systemic infections;
AND has an epidemiological link to a suspected or confirmed animal cases or contaminated animal products;
Probable case: A suspected case that has a positive reaction to allergic skin test (in non-vaccinated individuals);
LABORATORY CONFIRMATION:
Isolation of Bacillus anthracis from a clinical specimen (e.g., blood, lesions, discharges)
Demonstration of B. anthracis in a clinical specimen by microscopic examination of stained smears (vesicular fluid,
180
Page 1 of 2
Philippine Integrated Disease
Surveillance and Response
Measles
(ICD 10 Code: B05)
Name of DRU:
Type: RHU
Address:
Govt Laboratory
I. PATIENT
INFORMATION:
Patient Number:
Middle Name
Complete Address:
MM
DD
MM
Date Admitted/
Seen/Consult
YY
Date of Report:
Male
Female
MM
DD
Age:
YY
Days
Months
Years
Date of
Birth:
DD
YY
DD
Clinic
Airport/Seaport
Last Name
MM
Sex:
District:
ILHZ:
Patient Admitted? Yes No Unknown
Private Hospital
Private Laboratory
MM
Date Onset
of Illness
DD
YY
YY
Date of Investigation:
Runny nose/coryza: o Y o N o U
Red eyes/conjunctivitis: o Y o N o U
oY oN o U
oY o N o U
V. LABORATORY TESTS:
Collected?
If YES, date
taken
Serum
Y N
Dried blood
Y N
NP swab
Y N
Urine
Y N
NP aspirate
Y N
Throat swab
Y N
Specimen
Date sent to
RITM
Date result
OUTCOME
Laboratory Confirmed
Alive
Epidemiologically-linked
Died
Clinically-confirmed
Unknown
FINAL DIAGNOSIS
Discarded Case
181
Page 2 of 2
Measles
CASE DEFINITION/CLASSIFICATION:
Suspected
Clinically-confirmed: A suspected measles case, that, for any reason, is not completely investigated*
(e.g. death before investigation, no blood sample) or has equivocal laboratory test results.
case: Any individual, regardless of age, with the following signs and symptoms:
history of fever (38C or more) or hot to touch; and
generalized non-vesicular rash of 3 or more days duration; and,
at least one of the following: cough, coryza, or conjunctivitis
*Such cases represent failures of the surveillance system to adequately classify a case
Discarded or not measles case: A suspected measles case with an adequate specimen that is not
serologically confirmed or is confirmed positive for other diseases such as rubella or dengue.
LABORATORY CONFIRMATION:
Note: The therapeutic dosage of Vitamin A for measles cases should be given upon diagnosis regardless of
when the last dose of vitamin A capsule was given.
182
Page 1 of 2
Meningococcal Disease
(ICD 10 Code: A39)
Name of DRU:
Type: RHU
Address:
Govt Laboratory
Patient Number:
I. PATIENT
INFORMATION:
Private Laboratory
Middle Name
Sex:
Male
Female
Clinic
Airport/Seaport
Last Name
MM
Complete Address:
District:
Private Hospital
DD
YY
Age:
Days
Months
Years
Date of
Birth:
ILHZ:
Occupation:
Name Workplace:
Address of Workplace:
Name of School:
Address of School:
If student:
Admitted?
II. CLINICAL
INFORMATION: Yes No
Signs and
Symptoms:
Unknown
Fever
Headache
Maculopapular rash
Petechia
Purpura
Other lesions:
Clinical Presentation:
Meningitis
Septicemia
Both
Date Admitted/
Seen/Consult
MM
DD
Seizure
Stiff neck
Vomiting
Change of sensorium
Drowsiness
Other signs / symptoms:
Case Classification:
Suspected Case
Probable Case
Confirmed Case
YY
Date Onset
of Illness
MM
DD
YY
Malaise
Cough
Sore throat
Runny nose
Dyspnea
Outcome:
Alive
Died, Date Died _____/_____/_____
Unknown
III. CASE
Were blood/CSF extracted before the first dose of antibiotics was given to the patient?
MANAGEMENT:
Yes No Unknown
If YES, date
taken
MM
DD
Type of laboratory
test done
YY
Positive for:
N I U ND
N I U ND
Gram stain
N I U ND
Culture
MM
DD
YY
CSF
MM
MM
Blood
DD
DD
Results
N=Negative; I=Indeterminate; U-Unknown; ND= Not Done
YY
Positive for:
YY
Culture
Positive for:
Date result
MM
DD
YY
MM
DD
YY
MM
DD
YY
MM
DD
YY
N I U ND
183
Page 2 of 2
Meningococcal Disease
V. PAST HISTORY: Did the PATIENT or CLOSE CONTACT/S interact with a suspected or confirmed meningococcal case
within 2 weeks before onset of illness?
Where did the patient or close contact/s interact with the meningococcal case?
When? MM/DD/YY
Number of Days?
If yes, where?
Yes No Unknown
Did a CLOSE CONTACT/S of the patient travel within 2 weeks prior to illness? If yes, who and where?
Yes No Unknown
Did the PATIENT attend any social gathering within 2 weeks prior to illness?
If yes, where?
Yes No Unknown
Did the PATIENT have upper respiratory tract infection within 2 weeks prior to illness? Yes
No Unknown
Did a CLOSE CONTACT/S have upper respiratory tract infection within 2 weeks prior to the patients illness?
Yes No Unknown,
If Yes, who?
CASE DEFINITION/CLASSIFICATION:
Suspected case: A person with sudden onset of fever (>38.5C rectal or >38.0C axillary) and one or more
of the following:
neck stiffness
altered consciousness
other meningeal signs
petechial or purpural rash
Note:
In patients <1 year, suspect meningitis when fever is accompanied by bulging fontanels
Probable case: A suspected case as defined above AND with Turbid cerebrospinal fluid (with or without
positive Gram stain) OR ongoing epidemic and epidemiological link to a confirmed case.
LABORATORY CONFIRMATION:
184
Page 1 of 2
Philippine Integrated Disease
Surveillance and Response
Neonatal Tetanus
Name of DRU:
Type: RHU
Address:
Govt Laboratory
Patient Number:
I. PATIENT
INFORMATION:
Middle Name
Complete Address:
MM
DD
YY
Date of Report:
MM
Date Admitted/
Seen/Consult
MM
DD
Age in days:
YY
Date of
Birth:
DD
DD
Clinic
Airport/Seaport
Last Name
MM
Male
Female
Sex:
District:
ILHZ:
Patient Admitted? Yes No Unknown
Private Hospital
Private Laboratory
YY
YY
Date of Investigation:
Date Onset of
Illness
Mothers Full Name:
MM
DD
YY
After 2 days of life, did the baby have convulsions (stiffness or fits)?
Yes No Unknown
Yes No Unknown
Yes No Unknown
Yes No Unknown
Immunization Status
card:
ceived?_____ doses
TT1:_____/_____/_____
____unknown
oN
TT2:_____/_____/_____
TT3:_____/_____/_____
TT4:_____/_____/_____
TT5:_____/_____/_____
oU
o Yes
o No
o Unknown
o Hospital/lying-in/clinic
o Scissors o Blade
o MIdwife
o No
o Unknown
o Povidone iodine
OUTCOME
Suspected Case
Alive
Confirmed Case
Died
Unknown
185
Page 2 of 2
Neonatal Tetanus
CASE DEFINITION/CLASSIFICATION:
Suspected Case: Any neonatal death between 3-28 days of age in which the cause of death is unknown;
or any neonate reported as having suffered from neonatal tetanus between 3-28 days of age and not
investigated.
Confirmed Case: Any neonate ( = 28 days of life) that sucks and cries normally during the first 2 days of
life, and becomes ill between 3 to 28 days of age and develops both an inability to suck and diffuse muscle
rigidity (stiffness), which may include trismus, clenched fists or feet, continuously pursed lips, and/or curved
back (opisthotonus).
OR
NOTE: Neonatal tetanus case classification is based solely on clinical criteria. Any neonatal death occurring in
babies 3-28 days old with no apparent cause should be suspected as NT and evaluated according to the
above criteria. In calculating age, the day of birth is considered the first day of life (i.e., the baby is 1 day old
on the day he/she was born).
Protection at Birth (PAB) is defined as any of the following:
Regardless of interval:
2 TTV doses during the pregnancy with the youngest child, or
1 TTV dose during the pregnancy with the youngest child plus 2 doses prior to the pregnancy, or
3 TTV doses prior to the pregnancy with the youngest child
186
Page 1 of 2
Type: RHU
Address:
I. PATIENT
INFORMATION:
Govt Laboratory
Patient Number:
Private Laboratory
Middle Name
Complete Address:
Sex:
ILHZ:
Male
Female
MM
Date Admitted/
Seen/Consult
Airport/Seaport
DD
Age:
YY
Days
Months
Years
Date of
Birth:
DD
YY
Clinic
Last Name
MM
District:
Private Hospital
MM
DD
YY
Are there other members of household/community who shared the same meal?
Unknown
OUTCOME
Suspected Case
Alive
Confirmed Case
Died
Unknown
Name of DRU:
Type: RHU
Address:
I. PATIENT
INFORMATION:
Govt Laboratory
Patient Number:
Sex:
Date Admitted/
Seen/Consult
Private Laboratory
Middle Name
Complete Address:
Patient Admitted? Yes No Unknown
Private Hospital
Male
Female
MM
DD
YY
Airport/Seaport
Last Name
MM
Date of
Birth:
Clinic
DD
Days
Months
Years
Age:
YY
MM
DD
YY
Yes No
Unknown
OUTCOME
Suspected Case
Alive
Confirmed Case
Died
Unknown
CASE DEFINITION/CLASSIFICATION:
Confirmed case: A suspected case in which laboratory tests (biologic or environmental) have confirmed
exposure.
LABORATORY CONFIRMATION:
187
Page 2 of 2
Type: RHU
Address:
I. PATIENT
INFORMATION:
Govt Laboratory
Patient Number:
Private Laboratory
Middle Name
Complete Address:
Sex:
MM
Date Admitted/
Seen/Consult
Male
Female
Airport/Seaport
DD
Age:
YY
Days
Months
Years
Date of
Birth:
DD
YY
Clinic
Last Name
MM
District:
ILHZ:
Patient Admitted? Yes No Unknown
Private Hospital
MM
DD
YY
Are there other members of household/community who shared the same meal?
Unknown
OUTCOME
Suspected Case
Alive
Confirmed Case
Died
Unknown
Name of DRU:
Type: RHU
Address:
I. PATIENT
INFORMATION:
Govt Laboratory
Patient Number:
Sex:
Date Admitted/
Seen/Consult
Private Laboratory
Middle Name
Complete Address:
Patient Admitted? Yes No Unknown
Private Hospital
MM
Male
Female
DD
YY
Airport/Seaport
Last Name
MM
Date of
Birth:
DD
MM
OUTCOME
Suspected Case
Alive
Confirmed Case
Died
Unknown
188
Days
Months
Years
Age:
YY
Are there other members of household/community who shared the same meal?
Clinic
Unknown
DD
YY
Page 1 of 2
Rabies
(ICD 10 Code: A82)
Name of DRU:
Type: RHU
Govt Laboratory
Address:
I. PATIENT
INFORMATION:
Patient Number:
Middle Name
Complete Address:
Male
Female
Sex:
MM
Date Admitted/
Seen/Consult
DD
DD
Age:
YY
Days
Months
Years
Date of
Birth:
YY
Clinic
Airport/Seaport
Last Name
MM
District:
ILHZ:
Patient Admitted? Yes No Unknown
Private Hospital
Private Laboratory
Date Onset of
Illness
MM
DD
YY
dog cat
Yes
domestic
bat
Unknown
Other, specify_______________________
No
Unknown
stray
wild
died
killed intentionally
Patient History:
Vaccinated
Wound cleaned?:
Unvaccinated
Unknown
Yes No Unknown
OUTCOME
Suspected Case
Alive
Probable Case
Died
Confirmed Case
Unknown
CASE DEFINITION/CLASSIFICATION:
LABORATORY CONFIRMATION:
189
Page 2 of 2
Rabies
Name of DRU:
Type: RHU
Govt Laboratory
Address:
I. PATIENT
INFORMATION:
Patient Number:
Private Laboratory
Middle Name
Complete Address:
Male
Female
Sex:
MM
Date Admitted/
Seen/Consult
DD
Airport/Seaport
DD
Age:
YY
Days
Months
Years
Date of
Birth:
YY
Clinic
Last Name
MM
District:
ILHZ:
Patient Admitted? Yes No Unknown
Private Hospital
Date Onset of
Illness
MM
DD
YY
dog cat
Yes
domestic
Unknown
bat
Other, specify_______________________
No
Unknown
stray
wild
died
killed intentionally
Patient History:
Vaccinated
Wound cleaned?:
Unvaccinated
Unknown
Yes No Unknown
OUTCOME
Suspected Case
Alive
Probable Case
Died
Confirmed Case
Unknown
190
Address:
I. PATIENT
INFORMATION:
Middle Name
Last Name
Complete Address:
MM
Male
Sex:
Female
District:
DD
YYYY
Age:
Days
Months
Years
Date of
Birth:
ILHZ:
MM
DD
Date onset of
illness
DD
YYYY
TIME (hh:min:sec)
___:___:___ AM/PM
MM
YYYY
DD
YYYY
Date of Investigation:
MM
DD
YYYY
TIME (hh:min:sec)
____:____:____ AM / PM
TIME (hh:min:sec)
___:___:___ AM/PM
______days _____hours
II. TYPE OF SERIOUS AEFI (See back page for descriptions): check all that apply
1. LOCAL
Injection site abscess
Lymphadenitis
Severe local reaction (redness
and/or swelling centered at the
site of injection)
Osteitis/osteomyelitis
Persistent screaming
(inconsolable continuous
crying lasting at least 3 hours)
Sepsis
Thrombocytopenia
Toxic shock syndrome
DETAILS OF VACCINE
Dose
Number/vial
Lot/Batch
number
Manufacturer
Expiry date
Dose
Number/
vial
Lot/Batch
number
Manufacturer
Expiry date
Did the patient receive any vaccination within 4 weeks prior to this adverse event? Y N U (If YES, complete the information below).
VACCINE/S
(BCG, DPT, OPV, Measles,
HBV, others)
DETAILS OF VACCINE
Dose number
(single/multiple)
Lot/Batch
number
Manufacturer
Expiry date
Date given
Birth defects: Y N U
Y N U
_______________________________________________________
Does the patient had history of similar reaction? Y N U
_____________________________________________________
CASE DEFINITION:
Suspected AEFI case: Any individual that experience a serious condition any time after he or she received an immunization and is considered by a health worker (e.g., midwife, nurse, physician) to be possibly related to that immunization.
177
Page 2 of 2
Vaccine-related
Coincidental
Unknown
Injection Reaction
Final diagnosis:___________________________________
VI. OUTCOME:
Outcome: Alive
Died
Unknown
Definition of Terms:
An adverse event following immunization (AEFI) is defined as a medical incident that takes place after an immunization, causes concern,
and is believed to be caused by immunization.
A cluster of AEFI is defined as two or more cases of the same adverse event related in time, place or vaccine administered.
Serious medical condition is defined as those that are life-threatening and those that result in hospitalization (or prolonged hospitalization),
disability (or have the potential to result in disability) or death.
LOCAL ADVERSE EVENTS:
Injection-Site Abscess: Occurrence of a fluctuant or draining fluid-filled lesion at the site of injection with or without fever.
Lymphadenitis (includes suppurative lymphadenitis): Occurrence of either: at least one lymph node, 1.5 cm in size (one adult finger
width) or larger; or a draining sinus over a lymph node. Almost exclusively caused by BCG and then occurring within 2 to 6 months after
receipt of BCG vaccine, on the same side as inoculation (mostly axillary).
Severe local reaction: Redness and/or swelling centered at the site of injection and one or more of the following: swelling beyond the
nearest joint; pain, redness and swelling of more than 3 days duration; or requires hospitalization.
CENTRAL NERVOUS SYSTEM ADVERSE EVENTS:
Acute Paralysis
Acute onset of flaccid paralysis within 4 to 30 days of receipt of oral polio-virus vaccine (OPV), or within 4 -75 days after contact with
a vaccine recipient, with neurological deficits remaining 60 days after onset, or death.
Guillain-Barr Syndrome (GBS): Acute onset of rapidly progressive, ascending, symmetrical flaccid paralysis, without fever at onset of
paralysis and with sensory loss. Cases are diagnosed by cerebrospinal fluid (CSF) investigation showing dissociation between cellular
count and protein content. GBS occurring within 30 days after immunization should be reported.
Encephalopathy: Encephalopathy is an acute onset of major illness temporally linked with immunization and characterized by any two of
the following three conditions: Seizures; Severe alteration in level of consciousness lasting for one day or more; and Distinct change in behavior lasting one day or more. Cases occurring within 72 hours after vaccination should be reported.
Encephalitis: Encephalitis is characterized by encephalopathy and signs of cerebral inflammation and, in many cases, CSF pleocytosis
and/or virus isolation. Any encephalitis occurring within 1 to 4 weeks following immunization should be reported.
Meningitis: Acute onset of major illness with fever, neck stiffness/positive meningeal signs (Kernig, Brudzinski). Symptoms may be subtle to
similar to those of encephalitis. CSF examination is the most important diagnostic measure: CSF pleocytosis and/or detection of microorganism (Gram stain or isolation).
Seizures: Seizures lasting from several minutes to more than 15 minutes and not accompanied by focal neurological signs or symptoms.
Febrile Seizures or Afebrile Seizures. Onset is usually 0 to 2 days.
Anaphylactoid Reaction (acute hypersensitivity reaction): Exaggerated acute reaction, occurring within 2 hours after immunization,
characterized by one or more of the following: (1) wheezing and shortness of breath due to bronchospasm; (2) laryngospasm/laryngeal
edema; (3) one or more skin manifestations, e.g. hives, facial edema, or generalized edema.
Anaphylactic Shock: Circulatory failure (e.g. alteration of the level of consciousness, low arterial blood pressure, weakness or absence of
peripheral pulses, cold extremities secondary to reduced peripheral circulation, flushed face and increased perspiration) with or without
bronchospasm and/or laryngospasm/laryngeal edema leading to respiratory distress occurring immediately (0 to1 hr) after immunization.
Neuritis: Dysfunction of nerves supplying the arm/shoulder/gluteal area without other involvement of nervous system. A deep steady, often
severe aching pain in the shoulder and upper arm or gluteal area followed in days or weakness by weakness and wasting in arm/shoulder/
gluteal muscles. Sensory loss may be present, but is less prominent. May present on the same or the opposite side to the injection and
sometimes affects both arms or gluteal area. Onset is usually 2 to 28 days.
Disseminated BCG infection: Disseminated infection occurring within 1 to 12 months after BCG vaccination and confirmed by isolation of
Mycobacterium bovis BCG strain.
Hypotensive-Hyporesponsive Episode (shock collapse): Sudden onset of paleness, decreased level or loss of responsiveness, decreased level or loss of muscle tone (occurring within 24 hours of vaccination). The episode is transient and self -limiting.
Osteitis/Osteomyelitis: Inflammation of the bone either due to BCG immunization (occurring within 8 to 16 months after immunization) or
caused by other bacterial infection.
Persistent Screaming: Inconsolable continuous crying lasting at least 3 hours accompanied by high-pitched screaming. Onset 0 to 24 hrs.
Sepsis: Acute onset of severe generalized illness due to bacterial infection and confirmed by positive blood culture.
Thrombocytopenia: Platelet count of 100,000 cells or less per mm3. Onset is 15 to 35 days.
Toxic-Shock Syndrome: Abrupt onset of fever, vomiting and watery diarrhea within a few hours of immunization, often leading to death
within 24-48 hours.
178